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Objective: Growth delay in cystic ﬁbrosis is frequent and is usually the result of several interacting causes. It most often derives from severe
respiratory impairment and severe malabsorption. There are however patients whose clinical condition is not severe enough to be held accountable
for this phenomenon. We aimed at describing patients who showed growth delay, who were not affected by severe pulmonary disease or
malabsorption and who, when tested, showed a reduced GH secretion after stimulation with conventional agents. We noticed a disproportionately
large prevalence of growth hormone (GH) release deﬁcit (GHRD) in pediatric cystic ﬁbrosis (CF) patients.
Patients and methods: We examined all patients under our care in the period 2006–11, who were older than 5 and younger than 16 years old.
We focussed on those who fell below the 3rd height percentile, or whose growth during the previous 18 months faltered by N2 SD, and who did
not present clinical conditions that could reasonably explain their failure to thrive. These patients were subjected to standard GH provocative
tests.
Results: Out of 285 who matched the age criterion, 33 patients also matched the height percentile criterion. While 15/33 suffered clinical conditions
that could reasonably explain their failure to thrive, 18/33 underwent GH release provocative tests and 12/18 showed a release deﬁcit.
Conclusions: We conclude that impaired GH secretion is more frequent among CF patients compared to the prevalence of GH deﬁciency in the
general population and that GH release impairment may be an independent cause of growth delay in CF. Our ﬁndings are in agreement with recent
studies that have described low GH levels in CF piglets and in neonates with CF [1].
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Growth hormone; Growth retardation; Growth hormone deﬁciency1. Introduction
Monitoring growth is a priority in the clinical management of
cystic fibrosis (CF) patients.⁎ Corresponding author at: Centro Regionale Veneto per la Fibrosi Cistica,
Azienda Ospedaliera Universitaria Integrata di Verona Piazzale Stefani 1,
37126 Verona, Italy. Tel.: +39 045 812 3740; fax: +39 045 812 2042.
E-mail address: baroukh.assael@ospedaleuniverona.it (B.M. Assael).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2012.08.003Poor linear growth in patients affected by CF is generally
thought to be caused by concomitant severe complications
(pulmonary disease, malabsorption, diabetes, etc.). Although it is
certainly true that these clinical conditions affect growth (and we
have recently documented the correlation between low growth
and reduced long-term lung function in CF), it is also true that
reduced growth may be present in patients whose clinical
condition is not severe enough to be held accountable for this
phenomenon [2,3].by Elsevier B.V. All rights reserved.
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struck – at two centers in Italy and one center in Israel – by what
appears to be a relatively high prevalence of growth hormone
(GH) release deficiency. We wish to describe the GH deficient
patients under our care and to discuss the potential mechanisms
involved.
Though there have been several trials investigating the
effects of growth hormone therapy in CF patients (see Hardin
[4] for an exhaustive review) showing that it may be beneficial
in CF patients without a demonstrable GH deficit, this is the
first study to assess the CF population for the presence and
prevalence of true GH release deficiency.
2. Patients and methods
The cystic fibrosis centers of Verona (Italy), Brescia (Italy)
and Petah Tikva (Israel) participated in this study. Each center
director reviewed patients' records to ascertain the prevalence
of growth retardation. All patients attending the centers in the
period 2006–2011, who were older than 5 and younger than
16 years old, were included.
CF was diagnosed based on commonly accepted criteria,
i.e. abnormal chloride sweat test (N60 mEq/l), and the presence
of disease-causing mutations as well as typical clinical manifes-
tations [5].
We only included patients [1] whose nutrition level was
considered adequate, with normal caloric intake [2], whose
pancreatic insufficiency was adequately corrected by pancreatic
enzymes supplementation to reach no steatorrhea, even in the
presence of a low bodymass index (BMI) [3], without severe liver
abnormalities [4], whose pulmonary disease was not severe,
defined as Forced expiratory volume in one second (FEV1)b60%
of predicted [5], who were not on high dose steroids (defined as
prednisoneN1 mg/kg daily) for longer than 1 month during the
previous 6 months. We also excluded patients with [1] celiac
disease [2], CF related diabetes [3], reflux gastroesophageal
disease [4], milk protein intolerance or [5] other conditions
associated with growth retardation.
Relevant tests and measurements were height, height percen-
tile based on the Center for Disease Control and Prevention
(CDC) charts [6] height velocity, body mass index, and bodyTable 1
Characteristics at birth and at CF diagnosis (M = male, F = female).
Gender Gestational age
(wk)
Weight
(g and percentile)
Le
(c
1 M 39 3310 45 52
2 F 38 3225 66 49
3 M 39 3870 92 50
4 F 40 2740 7 46
5 F 38 2990 43 49
6 F 38 2550 10 47
7 F 36 3010 83 49
8 F 41 4100 97 52
9 M 40 2720 3 47
10 F 40 3700 84 46
11 M 38 2800 15 N
12 M 42 3500 52 Nweight. Neonatal length and body weight and gestational age at
birth were recorded where available. Growth deficit was defined
as height below the 3rd percentile. Bone age was assessed based
on the Tanner–Whitehouse 3 (TW3) method [7]. IGF-1 SD-
scores were calculated based on Clayton PE [8]. Brain MRI was
performed to ascertain pituitary abnormalities.
GH release stimulation tests were done per standard clinical
care at each of the centers with two commonly accepted agents.
Each child was tested twice (with arginine and insulin at
Verona, with arginine and clonidine at Brescia, with clonidine
and glucagon at Petah Tikva). Arginine was administered to
fasting patients at 0.5 g/kg (max 30 g) intravenously over
30 min. Sampling was done at −30, 0, 30, 60, 90 and 120 min.
Clonidine was administered to fasting patients at 0.15 mg/m2
orally with blood drawn at 0, 30, 60, 90, 120 and 150 min.
Insulin was administered at 0.08 IU/kg (max 2 IU) i.v. to
fasting patients with blood drawn at −15, 0, 10, 15, 20, 30,
60 min [9–11].
Patients were considered to be GHRD if both tests gave peak
GH values below 10 ng/ml, according to the most recent
published guidelines, i.e. the GH Research Society guidelines
for the diagnosis and treatment of GH deficiency in childhood
and adolescence [12].
All patients gave their informed consent to their data being
treated anonymously for the purpose of the present report. The
study protocol was approved by the Institutional Review Board
of the hospital of Verona as this was the institution of the
principal investigator.
3. Results
In total, 285 patients between 5 and 16 years of age were
followed at our three centers during the period 2006–11. Of
these patients, 33 showed a growth deficit as defined above. All
patients were prepubertal.
Of these 33 patients, 15 suffered clinical conditions that could
reasonably explain their failure to thrive (see above for exclusion
criteria). GH release was tested only in the remaining 18 patients
and found to be abnormally low in 12. Table 1 shows that patients
had normal weight and length for gestational age at birth. Table 2
shows that all patients exhibited severe growth retardation asngth
m and percentile)
Sweat chloride
(mEq/l)
Mutations
.0 87 91 1717-1 G A/F508del
.5 66 106 F508del/G85E
.0 46 120 F508del/N1303K
.0 2 95 F508del/F508del
.0 56 97 F508del/991del5
.0 19 113 2183AA G/N1303K
.0 85 99 I507del/711+5 G A
.0 50 113 F508del/W1282X
.0 2 141 F508del / F508del
.0 3 120 F508del/W1282X
ot available – 103 S549N/W1282X
ot available – 95 5 T/unknown
Table 2
Characteristics at the time of testing.
Age at testing
(year/month)
Height
(cm and
percentile)
Weight
(kg and
percentile)
Body mass
(index and
percentile)
Growth (cm/year) Bone age
deficit (yr)
FEV1 (% predicted)
Before After 1 year
treatment
Before After 1 year
treatment
1 11 y 0 m 130.0 1 26.7 2 15.8 11 5.0 9.5 –3.0 80 93
2 6 y 7 m 108.0 2 15.0 0 12.9 1 3.0 8.5 –3.0 80 78
3 7 y 3 m 108.5 0 18.1 1 15.4 28 4.0 9.0 –2.5 65 87
4 11 y 8 m 135.5 3 28.8 3 15.7 7 5.5 n.a. –2.5 68 n.a.
5 11 y 11 m 135.5 2 27.4 1 14.9 3 5.5 n.a. –3.0 69 n.a.
6 10 y 11 m 130.0 2 27.9 6 16.5 20 3.0 n.a. –3.0 63 n.a.
7 12 y 0 m 136.0 1 36.5 15 19.7 49 5.0 n.a. –2.5 84 n.a.
8 10 y 10 m 126.7 1 26.6 3 16.4 21 3.9 7.0 –3.0 95 103
9 8 y 7 m 115.0 0 22.1 5 16.7 45 1.3 8.1 –3.0 115 115
10 9 y 3 m 121.6 2 22.8 3 15.4 17 4.6 n.a. –3.0 105 n.a.
11 4 y 6 m 92.0 0 14.0 0 16.5 69 2.0 8.0 Not available Too young 95
12 7 y 11 m 110.4 0 19.8 1 16.2 58 3.0 6.6 –3.0 120 120
n.a. = not available because patients have not yet reached 1 year of treatment.
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peak GH values after stimulation, which was very low in some
patients and lower than 10 mg/l in all of them. IGF1 was
available in 10/12 patients. Six values were below the median
value for age. Pituitary MRI was normal in all patients for site,
volume and parenchyma.
All 12 patients with an abnormal GH response were started on
commercially available rhGH as per standard prescribing infor-
mation, i.e. 0.033 mg/kg/day subcutaneously for 6 days/week. In
those patients who completed 1 year of treatment with rhGH
height velocity showed a marked improvement. FEV1 improved
in 3/6 and remained stable in the others.
Since five of the 12 patients started less than 1 year ago,
follow-up data are only available for 7 patients. They are
summarized in Table 2. None of these patients experienced
pubertal growth spurt.
All patients followed at our centers undergo routine glucose
tolerance tests yearly and blood glucose levels were monitored
as per hrGH standard prescribing information. We used test
strips at home and glycated hemoglobin measurements at our
centers without detecting any significant adverse reactions to
rhGH.Table 3
GH release test results.
After 1st test ng/ml After 2nd test ng/ml IGF 1 ng/ml IGF 1 SD-score
1 1.4 1.7 Not done Not done
2 8.9 5.4 Not done Not done
3 6.1 4.4 168 0.56
4 7.0 4.5 306 0.13
5 2.8 b0.2 298 −0.22
6 3.6 7.1 283 0.23
7 9.0 7.1 214 −1.10
8 0.5 7.9 187 −0.85
9 5.3 6.3 100 −0.89
10 6.0 8.6 146 −0.70
11 Not done 4.8 70 −0.92
12 4.4 8.1 161 0.344. Discussion
Three large CF centers independently noted among their
patients a surprisingly high prevalence of patients with GHRD.
Each center followed internationally accepted guidelines and
tested GH release using two commonly accepted agents, differing
only in the ones they chose. In our cohort of 285 CF patients, we
tested 18 and found 12 with GH release deficit. Prevalence of
patients with GHRD in the general population is consistently
reported to be in the 0.02–0.03% range [13,14]. Prevalence in our
CF patient population was at least 12/285 or 4.21%, i.e. 200 times
as high. Since we tested only the 18 patients for whom the test
appeared to be indicated and did not screen all patients in our
cohort of 285 CF patients, it is still possible that we missed a few
GHRD cases, making true prevalence even higher.
Poor linear growth in patients affected by CF is generally
thought to be caused by concomitant severe complications
(pulmonary disease, malabsorption, etc.). However, evidence
suggests that even individuals with good clinical status do not
reach their full growth potential [2,15] and infants with CF have
been reported to be smaller than unaffected infants already at
birth [16–18]. In a study on 89 CF patients detected by neonatal
screening one third was found to be below the 3rd height
percentile and one half were found to be below the 10th percentile
[19]. Since the majority of infants with CF (except those with
meconium ileus) are asymptomatic at birth, it is likely that
prenatal and genetic factors directly influence growth.
CF patients show reduced growth even after appropriate
treatment is started. Lai et al. [20] found that approximately 40%
of infants were below the 5th percentile for weight and length at
the time of diagnosis, but deficits in length/height and weight
continued to be seen until adulthood, even after catch-up growth
had been induced by aggressivemanagement. This was confirmed
in other studies [21–24].
Mice with a null mutation in CFTR were found to be
severely growth retarded in weight and length compared with
wild-type controls [25]. Rogan et al. [1] reported that, like
humans, CF pigs were smaller than non-CF littermates.
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proportion of CF children, our data are in agreement with the
hypothesis that the somatotropic axis is affected by CFTR
malfunctioning. Previous studies have shown inconsistent data
on GH levels, basal and after stimulation, in CF patients: for a
review see Laursen et al. [26]. It should be noted that in those
earlier studies patients had widely variable conditions and
included patients with or without growth delays. Methods
applied were also very different. Since GH effects on growth
are prevalently mediated by IGF1, and circulating IGF1 levels
are more stable, most of the attention has been focussed on this
hormone, which has been consistently found to be lower in CF
(in human and in animal models) [1,25,27,28]. However, IGF1
levels vary greatly according to gender and age [8,29] and
although several of our patients had IGF1 levels in the lower
normal range, their number was too small to shed more light on
the role of IGF1 in CF.
We speculate that GH deficiency might be directly related to
the basic defect in CF. As recently shown by Hodges et al. [30] in
an animal model, loss of CFTR function in neurons may result in
poor growth and endocrine dysfunction. Rogan et al. [1] also
found that forskolin induced GH release from cultured pituitary
slices from CF pigs to a larger extent than from non-CF pigs,
suggesting that lack of CFTR impairs release of GH. Based on
their findings, they speculated that alterations in the somatotropic
axis in CF may explain why individuals with good clinical status
do not reach their full growth potential.
It is still under discussion whether CF patients may benefit
from treatment with rhGH as a non specific anabolic agent.
Published studies of GH use in children with CF have
demonstrated significant improvement in height velocity and
height Z score. Several reports suggest that GH treatment also
results in improved forced vital capacity, and multiple studies
have found improved clinical status as measured by decreased
hospitalizations and courses of intravenous antibiotics. In general
recombinant human GH improved almost all intermediate
measures of pulmonary function, height, and weight in patients
with CF. These studies have been reviewed by Hardin et al. [4]
and more recently by Phung et al. [31]. The results of another trial
were published more recently [32] showing that treatment with
rhGH in prepubertal children with CF was effective in promoting
growth, weight, lean body mass, lung volume, and lung flow
rates, and concluding that in CF its anabolic actions might be
beneficial. Respiratory function generally improved after 1-year
rhGH in our patients, but this was not the main aim of the
treatment.
We believe that intensive screening of CF patients to
identify those with GH activity impairment is warranted in
order to provide replacement treatment promptly for those who
are more likely to benefit from GH supplementation.
5. Conclusions
We found an increased prevalence of GH deficiency in CF
patients. Future studies are now needed to evaluate whether this
GH deficiency in CF is directly related to defective CFTR or
secondary.In the mean time, we recommend to test all CF patients
under the 3rd percentile for GH deficiency.Acknowledgments
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